Prexton Therapeutics

Prexton Therapeutics is the first spin-off company from EPP Fund. The company is developing programs in Parkinson’s disease focused on targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics is based in Geneva, Switzerland.

Latest News Entry
M&A of the Year: Prexton Therapeutics

Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

"The sale of Prexton Therapeutics to Lundbeck is a very strong validation of our model of founding companies based on spinning-off assets from Merck KGaA, Darmstadt, Germany and managing them very actively as a shareholder. We are very excited to see the program being acquired by Lundbeck, a leading company in the field of neurology, and feel this is a strong confirmation of the investment thesis on which Prexton was founded in 2012 by Francois Conquet and us, namely that modulating mGluR4 is a highly promising therapeutic approach for the sympomatic treatment of Parkinson`s Disease and dyskinesia.", said Jasper Bos, Ph.D., Vice-President and Head of Healthcare of M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, Board Member of Prexton.

Parkinson’s disease: Prexton announces initiation of phase II clinical testing

Study will evaluate first-in class treatment in six European countries

Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic

Forbion & Seroba co-led funding, forming international consortium of M Ventures, Ysios and Sunstone
Funding to finance two Phase II trials in Parkinson’s disease

Geneva, Switzerland and Amsterdam, The Netherlands, February 7, 2017 - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the closing of a Series B financing round of €29 million ($31M).

Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial

First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compound for treating Parkinson’s disease, will assess safety and tolerability.

Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round

Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including ...

all related news
all portfolio news